Helios Homoeopathy Limited 04213167 false 2025-07-01 2026-06-30 2026-06-30 The principal activity of the company is the manufacture and dispensing of homoeopathic remedies Digita Accounts Production Advanced 6.30.9574.0 true false 04213167 2025-07-01 2026-06-30 04213167 2026-06-30 04213167 bus:OrdinaryShareClass1 2026-06-30 04213167 core:CurrentFinancialInstruments 2026-06-30 04213167 core:CurrentFinancialInstruments core:WithinOneYear 2026-06-30 04213167 core:FurnitureFittingsToolsEquipment 2026-06-30 04213167 core:LandBuildings 2026-06-30 04213167 bus:SmallEntities 2025-07-01 2026-06-30 04213167 bus:AuditExemptWithAccountantsReport 2025-07-01 2026-06-30 04213167 bus:FilletedAccounts 2025-07-01 2026-06-30 04213167 bus:SmallCompaniesRegimeForAccounts 2025-07-01 2026-06-30 04213167 bus:RegisteredOffice 2025-07-01 2026-06-30 04213167 bus:Director1 2025-07-01 2026-06-30 04213167 bus:Director2 2025-07-01 2026-06-30 04213167 bus:Director3 2025-07-01 2026-06-30 04213167 bus:Director5 2025-07-01 2026-06-30 04213167 bus:Director6 2025-07-01 2026-06-30 04213167 bus:OrdinaryShareClass1 2025-07-01 2026-06-30 04213167 bus:PrivateLimitedCompanyLtd 2025-07-01 2026-06-30 04213167 bus:Agent1 2025-07-01 2026-06-30 04213167 core:FurnitureFittingsToolsEquipment 2025-07-01 2026-06-30 04213167 core:LandBuildings 2025-07-01 2026-06-30 04213167 core:LeaseholdImprovements 2025-07-01 2026-06-30 04213167 core:MotorVehicles 2025-07-01 2026-06-30 04213167 core:PlantMachinery 2025-07-01 2026-06-30 04213167 countries:EnglandWales 2025-07-01 2026-06-30 04213167 2025-06-30 04213167 core:CostValuation 2025-06-30 04213167 core:FurnitureFittingsToolsEquipment 2025-06-30 04213167 core:LandBuildings 2025-06-30 04213167 2024-07-01 2025-06-30 04213167 2025-06-30 04213167 bus:OrdinaryShareClass1 2025-06-30 04213167 core:CurrentFinancialInstruments 2025-06-30 04213167 core:CurrentFinancialInstruments core:WithinOneYear 2025-06-30 04213167 core:FurnitureFittingsToolsEquipment 2025-06-30 04213167 core:LandBuildings 2025-06-30 04213167 bus:OrdinaryShareClass1 2024-07-01 2025-06-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 04213167

Helios Homoeopathy Limited

Unaudited Filleted Financial Statements

for the Year Ended 30 June 2026

 

Helios Homoeopathy Limited

Contents

Company Information

1

Statement of Financial Position

2 to 3

Notes to the Unaudited Financial Statements

4 to 9

 

Helios Homoeopathy Limited

Company Information

Directors

Mr John Lee

Ms Roz Buckfield

Ms Janet Weddell

Mrs Maya Morgan

Mr John Morgan

Registered office

97 Camden Road
Tunbridge Wells
Kent
TN1 2QR

Accountants

Melrose Accountants 62 Florence Road
Brighton
East Sussex
BN1 6DJ

 

Helios Homoeopathy Limited

(Registration number: 04213167)
Statement of Financial Position as at 30 June 2026

Note

2026
£

2025
£

Fixed assets

 

Tangible assets

4

27,105

36,309

Investments

5

1,272,285

1,272,285

 

1,299,390

1,308,594

Current assets

 

Stocks

6

416,279

441,563

Debtors

7

593,335

569,379

Cash at bank and in hand

 

1,092,825

1,182,582

 

2,102,439

2,193,524

Creditors: Amounts falling due within one year

8

(337,352)

(472,285)

Net current assets

 

1,765,087

1,721,239

Total assets less current liabilities

 

3,064,477

3,029,833

Provisions for liabilities

(4,008)

(6,223)

Net assets

 

3,060,469

3,023,610

Capital and reserves

 

Called up share capital

9

100

100

Retained earnings

3,060,369

3,023,510

Shareholders' funds

 

3,060,469

3,023,610

For the financial year ending 30 June 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Income Statement.

Approved and authorised by the Board on 26 August 2026 and signed on its behalf by:
 

 

Helios Homoeopathy Limited

(Registration number: 04213167)
Statement of Financial Position as at 30 June 2026

.........................................
Mr John Morgan
Director

 

Helios Homoeopathy Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2026

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
97 Camden Road
Tunbridge Wells
Kent
TN1 2QR

These financial statements were authorised for issue by the Board on 26 August 2026.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

Foreign currency transactions and balances

Transactions in foreign currencies are translated at the exchange rate ruling at the date of the transaction, or, where forward cover has been arranged, at the contractual rate. Monetary assets and liabilities denominated in foreign currencies are retranslated at the exchange rates ruling at the balance sheet date or at a contractual rate if applicable and any exchange differences arising are taken to the profit and loss account in the season to which the contract relates.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Helios Homoeopathy Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2026

Except where otherwise required by accounting standards, full provision without discounting is made for all timing differences, which have arisen but not reversed at the balance sheet date. Deferred tax assets are recognised only to the extent that it is more likely than not that they will be recovered.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Plant and machinery

33% straight line

Motor vehicles

25% straight line

Leasehold improvements

over the term of the lease

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

 

Helios Homoeopathy Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2026

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Leases

Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged against profits as incurred.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 81 (2025 - 77).

 

Helios Homoeopathy Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2026

4

Tangible assets

Land and buildings
£

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 July 2025

37,650

517,835

555,485

Additions

-

18,871

18,871

At 30 June 2026

37,650

536,706

574,356

Depreciation

At 1 July 2025

37,650

481,526

519,176

Charge for the year

-

28,075

28,075

At 30 June 2026

37,650

509,601

547,251

Carrying amount

At 30 June 2026

-

27,105

27,105

At 30 June 2025

-

36,309

36,309

Included within the net book value of land and buildings above is £Nil (2025 - £Nil) in respect of long leasehold land and buildings.
 

5

Investments

2026
£

2025
£

Investments in subsidiaries

1,272,285

1,272,285

Subsidiaries

£

Cost or valuation

At 1 July 2025

1,272,285

Provision

Carrying amount

At 30 June 2026

1,272,285

At 30 June 2025

1,272,285

 

Helios Homoeopathy Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2026

6

Stocks

2026
£

2025
£

Other inventories

416,279

441,563

7

Debtors

Current

Note

2026
£

2025
£

Trade debtors

 

80,567

67,505

Amounts owed by related parties

455,791

454,000

Prepayments

 

46,977

31,374

Other debtors

 

10,000

16,500

   

593,335

569,379

 

Helios Homoeopathy Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 June 2026

8

Creditors

Creditors: amounts falling due within one year

2026
£

2025
£

Due within one year

trade creditors

66,099

149,526

Taxation and social security

139,118

131,452

Accruals and deferred income

53,373

25,181

Other creditors

12,599

12,599

Income tax liability

66,163

153,527

337,352

472,285

9

Share capital

Allotted, called up and fully paid shares

2026

2025

No.

£

No.

£

ordinary shares of £1 each

100

100

100

100

       

10

Dividends

Interim dividends paid

2026
£

2025
£

Interim dividend of £1,480.00 (2025 - £1,077.04) per each ordinary shares

148,000

107,704

 

 

11

Financial commitments, guarantees and contingencies

Amounts not provided for in the statement of financial position

The total amount of financial commitments not included in the statement of financial position is £414,780 (2025 - £71,963).